Jazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded to “Neutral” Rating by Cantor Fitzgerald

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by equities researchers at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report released on Wednesday,Briefing.com Automated Import reports.

Other research analysts have also issued research reports about the stock. TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Finally, Royal Bank of Canada lowered their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.80.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $4.55 during trading hours on Wednesday, reaching $144.22. 1,787,968 shares of the company traded hands, compared to its average volume of 669,349. The stock’s fifty day moving average is $125.42 and its 200 day moving average is $118.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $148.06. The stock has a market cap of $8.72 billion, a P/E ratio of 20.25, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 5,053 shares of company stock worth $617,442 in the last quarter. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $59,668,000. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after acquiring an additional 320,724 shares during the period. Ameriprise Financial Inc. grew its position in shares of Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the last quarter. Finally, GMT Capital Corp boosted its holdings in Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after acquiring an additional 296,800 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.